Related Experiment Video

Updated: Jul 19, 2026

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
08:27

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology

Published on: March 24, 2015

Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy

Angela L Zarling1, Joy M Polefrone, Anne M Evans

  • 1Beirne B. Carter Immunology Center and Department of Microbiology, University of Virginia, Charlottesville, VA 22908, USA.

Proceedings of the National Academy of Sciences of the United States of America
|September 27, 2006
PubMed

Insights

Cancer cells display unique phosphopeptides on their surface, which can be recognized by CD8+ T cells. These cancer-specific phosphopeptides represent promising targets for novel immunotherapies.

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Malignant transformation involves altered cellular protein phosphorylation.
  • Degradation of phosphoproteins can yield cancer-specific peptides.
  • These peptides may be presented by MHC class I molecules for T cell recognition.

Purpose of the Study:

  • To identify cancer-specific phosphopeptides presented on tumor cells.
  • To evaluate the potential of these phosphopeptides as targets for CD8+ T cell-based immunotherapies.

Main Methods:

  • Comparative analysis of phosphopeptides from melanoma, ovarian carcinoma, and B lymphoblastoid cells.
  • Mass spectrometry-based identification of phosphopeptides.
  • Assessment of CD8+ T cell recognition of identified phosphopeptides.

Main Results:

  • Identified 36 phosphopeptides presented on cancer cells.
  • Discovered 5 phosphopeptides common to both melanoma and ovarian carcinoma, but not B lymphoblastoid cells.
  • Demonstrated recognition of these cancer-specific phosphopeptides by CD8+ T lymphocytes.

Conclusions:

  • Differential phosphorylation contributes to the distinct phosphopeptide presentation in solid tumors.
  • Cancer-specific phosphopeptides are valid targets for T cell-mediated immunotherapy.
  • These findings support the development of phosphopeptide-based cancer vaccines.

More Related Videos

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis09:32

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis

Published on: October 15, 2021

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...